Ekso Bionics Holdings, Inc. (EKSO)
$1.61
Rating:
Recommendation:
Buy
| Symbol | EKSO |
|---|---|
| Price | $1.61 |
| Beta | 1.656 |
| Volume Avg. | 0.07M |
| Market Cap | 22.918M |
| Shares () | - |
| 52 Week Range | 0.62-1.88 |
| 1y Target Est | - |
| DCF Unlevered | EKSO DCF -> | |
|---|---|---|
| DCF Levered | EKSO LDCF -> | |
| ROE | -69.41% | Strong Sell |
| ROA | -44.40% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 49.05% | Neutral |
| P/E | -1.44 | Sell |
| P/B | 1.49 | Strong Buy |
Latest EKSO news
About
Download (Excel)Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.